BXTAccelyon becomes sole distribution partner for new transperineal prostate biopsy device

12th July 2017: BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, is proud to announce it has become the sole distribution partner outside North America for the PrecisionPointTM Transperineal Access System, a new medical device that is set to revolutionise prostate biopsies.

Developed in response to the increased adoption of active surveillance and the disadvantages in transrectal biopsy approaches, PrecisionPointTM which has been developed and patented by the US based company Perineologic is the first FDA approved device that allows a free-handed transperineal biopsy of the prostate. The low-cost, disposable device represents a safer and more accurate method for urologists to detect potential incidents of prostate cancer at an earlier stage of progression, through its ability to systematically allow access to the whole prostate gland.